Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year
Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...
Replimune Group (NASDAQ:REPL) Price Target Raised to $27.00
Replimune Group (NASDAQ:REPL – Get Free Report) had its price target raised by investment analysts at BMO Capital Markets ...
Replimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock Surges
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...
Strong Buy Rating for Replimune Group Due to Promising RP1 + Opdivo Results and Favorable FDA Review
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...
Replimune price target raised to $21 from $17 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA review ...
Yahoo Finance5d
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
WOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies ...
The Pharma Letter4d
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
ETF Daily News3d
Replimune Group (NASDAQ:REPL) Trading Up 6% Following Analyst Upgrade
Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price shot up 6% during trading on Wednesday after BMO Capital Markets raised their price target on the stock from $18.00 to $27.00.
Replimune stock soars on FDA priority review for melanoma treatment
Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...
Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy
Replimune Group ( REPL, Financials) shares surged 17% to $11.85 as of 10:18 a.m. ET Tuesday after the U.S. Food and Drug ...